New Enhancements to PlanMD, a Part of the InsightRT Suite of AI-Powered Decision Support Software for Radiation Oncology, Make It Even Easier to Use
Siris Medical, Inc., headquartered in Silicon Valley and Boston, announced the commercial release of PlanMD™ 2.0, an update of the first AI-powered decision support software for radiation oncologists. PlanMD enables radiation oncology clinical teams to leverage patient data and artificial intelligence to make better treatment decisions. PlanMD is the first and only tool that enables the physician to see the effect of editing contours in real-time, without re-optimizing or replanning. PlanMD complements Siris Medical’s QuickMatch™ software, which accelerates the treatment planning process by using artificial intelligence to quickly identify the most similar cases previously treated to inform planning decisions and help reduce dose to critical structures.
PlanMD 2.0 enhancements came primarily from input received from radiation oncologists who are the tool’s primary users. These physicians are busy, so the new version is designed to make the tool even faster and easier to use. New precision display functionality allows for greater efficiency and accuracy in structure evaluation and contouring, for both tumor and critical organs. More powerful and granular contour exploration functionality also permits faster insights into the impacts of contouring changes on dose. And a host of smaller, user-driven changes all combine to make PlanMD v2.0 even simpler and faster to use.
Dr. Marc Nash, Chief Medical Officer of Siris Medical and a UCSF-trained, board-certified radiation oncologist noted, “While the underlying prediction algorithms have performed well from the very beginning, it is only through extensive input from practicing radiation oncologists that we can truly ensure the ease of use and rapid results that busy clinicians demand. We are proud to count some of the nation’s leading cancer centers and radiation oncologists as our customers, and their feedback has helped us build an even better, easier to use clinical decision support tool to help physicians in their battle against cancer.”
Read More: Interview with Christopher McCann, CEO and Co-Founder, snap40
